Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Technology-Assisted Web Application for Consumer Access to a Nonprescription Statin Medication.
Nissen SE, Hutchinson HG, Wolski K, Watson K, Martin SS, Michos ED, Weintraub WS, Morris M, Cho L, Laffin L, Jacoby D, Ballantyne CM, Ekelund J, Birve F, Menon V, Strzelecki M, Ridker PM. Nissen SE, et al. Among authors: ballantyne cm. J Am Coll Cardiol. 2024 May 28;83(21):2080-2088. doi: 10.1016/j.jacc.2024.03.388. Epub 2024 Apr 8. J Am Coll Cardiol. 2024. PMID: 38599257 Free article.
Racial and ethnic disparities in cardiovascular disease - analysis across major US national databases.
Minhas AMK, Talha KM, Abramov D, Johnson HM, Antoine S, Rodriguez F, Fudim M, Michos ED, Misra A, Abushamat L, Nambi V, Fonarow GC, Ballantyne CM, Virani SS. Minhas AMK, et al. Among authors: ballantyne cm. J Natl Med Assoc. 2024 Feb 10:S0027-9684(24)00022-1. doi: 10.1016/j.jnma.2024.01.022. Online ahead of print. J Natl Med Assoc. 2024. PMID: 38342731
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.
Szarek M, Bhatt DL, Miller M, Brinton EA, Jacobson TA, Tardif JC, Ballantyne CM, Mason RP, Ketchum SB, Lira Pineda A, Doyle RT Jr, Steg PG; REDUCE-IT Investigators. Szarek M, et al. Among authors: ballantyne cm. J Am Coll Cardiol. 2024 Apr 23;83(16):1529-1539. doi: 10.1016/j.jacc.2024.02.016. Epub 2024 Mar 25. J Am Coll Cardiol. 2024. PMID: 38530686 Free article. Clinical Trial.
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.
Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. Koschinsky ML, et al. Among authors: ballantyne cm. J Clin Lipidol. 2024 Mar 29:S1933-2874(24)00033-3. doi: 10.1016/j.jacl.2024.03.001. Online ahead of print. J Clin Lipidol. 2024. PMID: 38565461
High lipoprotein(a): Actionable strategies for risk assessment and mitigation.
Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. Reyes-Soffer G, et al. Among authors: ballantyne cm. Am J Prev Cardiol. 2024 Apr 3;18:100651. doi: 10.1016/j.ajpc.2024.100651. eCollection 2024 Jun. Am J Prev Cardiol. 2024. PMID: 38646021 Free PMC article. Review.
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN.
Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, Navar AM, Nissen SE, Golberg AC, Brunham LR, Curcio D, Wuerdeman E, Neild A, Kling D, Hsieh R, Dicklin MR, Ference BA, Laufs U, Banach M, Mehran R, Catapano AL, Davidson MH. Nicholls SJ, et al. Among authors: ballantyne cm. Am Heart J. 2024 May 4;274:32-45. doi: 10.1016/j.ahj.2024.05.002. Online ahead of print. Am Heart J. 2024. PMID: 38705341 Free article.
1,025 results